NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Carrier Connect Data Solutions Inc. (TSX-V: CCDS; OTCQX: CCDSF), a rapidly expanding data centre company focused on acquiring and operating Tier II/III colocation infrastructure, has qualified to trade on the OTCQX® Best Market. Carrier Connect Data Solutions Inc. upgraded to OTCQX from the OTCQB® Venture Market.

Carrier Connect Data Solutions Inc. begins trading today on OTCQX under the symbol “CCDSF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Graduating to the OTCQX Market marks an important milestone for companies, enabling them to demonstrate their qualifications and build visibility among U.S. investors.

Mark Binns, Carrier’s CEO comments “Trading on OTCQX marks an important milestone, enhancing our visibility in the U.S. and making it easier for North American investors to access and trade our shares at this important time for the company.”

Trading in non-U.S. North American securities on OTC Markets reached $29.38B in the third quarter of 2026, representing an 84.22% increase over Q3 2025. OTC Markets recorded $203.47B in total dollar volume in Q3. North America ranked among the top home markets by trading volume during the quarter, highlighting sustained U.S. investor demand for internationally listed names.

About Carrier Connect Data Solutions Inc.
Carrier Connect Data Solutions’ mission is to roll up Tier II/III data centres internationally that specialize in delivering co-location and data center solutions to AI companies, service providers, enterprises and small businesses. Data centres are the physical locations that store computing machines and their related hardware equipment, such as servers, data storage drives, and network equipment. The current principal markets for the Company are Vancouver, Ottawa and Saint John, Canada, Rochester and Atlanta, USA and Perth, Australia. Carrier operates through two wholly-owned subsidiaries – PureColo Inc. and PureColo USA Inc.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our public markets: OTCQX® Best Market, OTCQB® Venture Market, OTCID™ Basic Market and Pink Limited™ Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets.

OTC Link ATS, OTC Link ECN, OTC Link NQB, OTC Overnight® and MOON ATS® are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC.

To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com.

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media@otcmarkets.com

ERAS-0015 at 32 mg QD achieved 44% confirmed ORR in 2L+ KRAS G12X PDAC, despite heavy pretreatment (84% in the 3L+ setting) and a high proportion of G12R mutations (44% of patients)

ERAS-0015 at 32 mg QD achieved 69% confirmed ORR in 2L+ KRAS G12D or G12V PDAC

ERAS-0015 at 32 mg QD achieved 60% confirmed ORR in post-ICI/platinum (2L/3L) KRAS G12X NSCLC

ERAS-0015 at 32 mg QD continued to be generally well tolerated, with mostly low-grade TRAEs and low rates of dose interruptions, reductions, and discontinuations

Early combination data with gemcitabine plus nab-paclitaxel, pembrolizumab, and panitumumab support ERAS-0015’s combination backbone potential

ERAS-4001 showed preliminary Phase 1 antitumor activity, favorable tolerability, and encouraging PK; dose escalation of the ERAS-0015 + ERAS-4001 combination expected to initiate in 2027

Conference call and live webcast today at 8:00 a.m. Eastern Time

SAN DIEGO, Nov. 20, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced positive updated U.S. Phase 1 monotherapy and initial combination data reinforcing the best-in-class potential of pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors. The Company confirms its plans to initiate a potentially registration-enabling trial in 2L+ lung cancer in the first half of 2027 and a Phase 3 trial in 1L lung cancer in the second half of 2027 to first half of 2028 timeframe; and is accelerating the planned initiation of a Phase 3 trial in 1L pancreatic cancer to the first half of 2027. The Company also announced encouraging initial U.S. Phase 1 monotherapy data for potential first-in-class pan-KRAS inhibitor ERAS-4001, supporting its combination potential with ERAS-0015.

“These compelling results highlight the strength and breadth of ERAS-0015’s clinical activity across several tumor types,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “We are particularly encouraged by confirmed responses in common KRAS mutation subtypes, including G12D and G12V, which together occur in nearly 70% of patients with pancreatic cancer. Importantly, we believe the robust clinical activity observed in this heavily pretreated population, which included a high proportion of patients whose tumors harbored less sensitive mutations, compares favorably with reported activity for other pan-RAS and mutant-selective inhibitors, subject to the limitations of cross-study comparisons. Additionally, we believe these efficacy results, coupled with generally well-tolerated safety data and low rates of dose interruptions, reductions, and discontinuations at 32 mg once daily, support advancing ERAS-0015 toward multiple potentially registration-enabling trials.”

Dr. Lim continued, “Early combination data demonstrating favorable tolerability results with chemotherapy, an immune checkpoint inhibitor, and an anti-EGFR antibody, together with preliminary clinical activity for ERAS-4001, strengthen our rationale for expanding ERAS-0015’s combination potential. We expect 2027 to be an important year for our RAS-targeting franchise as we plan to initiate potentially registration-enabling clinical trials in pancreatic and lung cancers and advance combination dose-escalation trials, including the planned ERAS-0015 plus ERAS-4001 combination.”

Key U.S. Phase 1 interim results for ERAS-0015 (AURORAS-1):

As of the data cutoff date, ERAS-0015 monotherapy at the pharmacologically active doses (PAD) of 16-32 mg once daily (QD) (N=122) was generally well-tolerated with favorable safety data, and demonstrated encouraging activity in key KRAS G12X tumors. Monotherapy responses shown are confirmed. All patients with responses at 32 mg QD in all tumor types remained on treatment.1,2

ERAS-0015 Monotherapy Showed Strong Anti-Tumor Activity Across Advanced KRAS-Mutant Cancers

  • KRAS G12X pancreatic ductal adenocarcinoma (PDAC) at 32 mg QD in the second-line or greater (2L+) setting1,2
    • 44% confirmed objective response rate (ORR) across all patients (N=25) with KRAS G12X mutations; 84% were treated in the third-line or later (3L+) setting and 44% had G12R mutations
    • 69% confirmed ORR in patients (N=13) with KRAS G12D or G12V PDAC, which represent nearly 70% of patients with PDAC. Of these patients, 77% were treated in 3L+
      • 63% confirmed ORR (N=8) in patients with KRAS G12D
      • 80% confirmed ORR (N=5) in patients with KRAS G12V
    • All (11 of 11) patients with confirmed responses and 6 of 11 patients with stable disease remained on treatment
  • KRAS G12X non-small cell lung cancer (NSCLC)1,2
    • 60% confirmed ORR (N=5) at 32 mg QD and 58% confirmed ORR (N=12) across the PAD range of 16-32 mg QD in the 2L or 3L setting following an immune checkpoint inhibitor and platinum-based chemotherapy (post-ICI/platinum)
    • Activity was observed across multiple KRAS mutation subtypes at 32 mg QD in the 2L+ setting:
      • 60% confirmed ORR (N=5) in patients with KRAS G12D mutations
      • 50% confirmed ORR (N=4) in patients with KRAS G12V mutations
    • At 32 mg QD in the 2L+ setting, all (5 of 5) patients with confirmed responses and all (5 of 5) patients with stable disease remained on treatment
  • KRAS G12X biliary tract cancer (BTC) at 32 mg QD in the 1L+ setting1
    • 75% confirmed ORR (N=4)
    • All (3 of 3) patients with confirmed responses remained on treatment

ERAS-0015 Monotherapy Continued to Be Generally Well-Tolerated with Favorable Safety Data in Expanded Patient Population1,5

  • Frequency and severity of treatment-related adverse events (TRAEs) remained consistent with the Company’s April and July 2026 interim data disclosures
  • Mostly low-grade TRAEs with no dose-limiting toxicities (DLTs) and low rate of dose interruptions, reductions, and discontinuations due to TRAEs
    • At 32 mg QD (N=54), TRAEs led to dose interruptions in 13.0% of patients and dose reductions in 16.7% of patients, and there were no dose discontinuations (0% of patients)
  • 100% median relative dose intensity (RDI) at 32 mg QD

Early ERAS-0015 Combination Data Support Further Development and Potential for Differentiation with Standard-of-Care Therapies3

  • ERAS-0015 plus gemcitabine + nab-paclitaxel (Days 1 and 15):
    • Generally well tolerated with favorable safety data and no unexpected safety signals
    • The DLT window was cleared through the 16 mg QD ERAS-0015 cohort with no DLTs
    • Currently dosing the 24 mg QD ERAS-0015 dose escalation cohort
    • Efficacy data not yet available
    • Clinical data support further development in 1L PDAC
  • ERAS-0015 plus pembrolizumab:
    • Generally well tolerated with favorable safety data and no unexpected safety signals
    • The DLT window was cleared through the 32 mg QD ERAS-0015 cohort with no DLTs
    • Multiple responses observed in multiple solid tumor types in dose escalation
    • Clinical data support further development in 1L NSCLC, including combination with carboplatin/pemetrexed/pembrolizumab (initiated in Q4)
  • ERAS-0015 plus panitumumab:
    • 16 mg QD ERAS-0015 was generally well tolerated with favorable safety data and no unexpected safety signals
    • Multiple responses were observed in dose escalation in patients with KRAS G12X colorectal cancer (CRC), including 2 ongoing confirmed partial responses (PR) in 2 patients treated at 24 mg QD who then dose reduced to 16 mg QD, and 1 unconfirmed PR (uPR) in 4 patients treated at 16 mg QD
    • Combination dose exploration ongoing; plan to make dose selection in 2027

Encouraging Preliminary ERAS-4001 Phase 1 Data Support Planned Combination with ERAS-00154

  • Favorable safety and tolerability data with predominantly low-grade adverse events and no TRAEs leading to treatment discontinuation
  • Pharmacokinetic (PK) results were encouraging and support continued dose escalation
  • Preliminary monotherapy antitumor activity supports ERAS-4001’s potential as a combination partner for ERAS-0015
  • Nonclinical data demonstrated that the combination of ERAS-0015 and ERAS-4001 targets both active- and inactive-state KRAS and exhibits synergistic activity in KRAS G12X-driven models, providing a rationale for further evaluation of this combination

Key Anticipated Milestones

ERAS-0015: AURORAS-1 and Phase 3 Trials

  • Potentially registration-enabling trial in patients with 2L+ RAS-mutant NSCLC expected to initiate in the first half of 2027
  • Phase 3 trial in patients with 1L PDAC accelerated to initiate in the first half of 2027
  • Phase 3 trial in patients with 1L RAS-mutant NSCLC expected to initiate in the second half of 2027 to the first half of 2028
  • Combination dose escalation and expansion data expected in 2027

ERAS-4001: BOREALIS-1 Trial

  • Initiation of combination dose escalation trial with ERAS-0015 planned for 2027

¹ Data cutoff date (DCO) September 1, 2026
² Includes responses confirmed after the data cutoff date
3 DCO October 14, 2026
4 As of November 9, 2026
5 As disclosed by the Company in April 2026, one Grade 3 TRAE of pneumonitis progressed to Grade 5 after withdrawal of supportive care per patient decision. The patient was a 66 year-old male with heavily pretreated metastatic pancreatic adenocarcinoma who received 24 mg of ERAS-0015. The patient had pulmonary metastases, a history of right lung cryoablation and no history of lung radiation. The patient presented to the ER approximately a month after starting ERAS-0015 with Grade 3 pneumonitis that was treated aggressively with immediate discontinuation of ERAS-0015, high dose steroids and infliximab. The patient requested withdrawal of supportive care and ultimately died of the event. No additional Grade 5 TRAEs have occurred

Virtual Investor Event Webcast Information
Erasca will hold a virtual investor event today, Friday, November 20, 2026 at 8:00 a.m. Eastern Time. To register for the event please click here. The live webcast and replay may be accessed by referring to Erasca’s website at Erasca.com/events.

About ERAS-0015
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile and has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic pancreatic adenocarcinoma. The ongoing AURORAS-1 Phase 1 trial is evaluating ERAS-0015 as a monotherapy and in combination with other therapies in patients with RAS-mutant solid tumors. Clinical data have demonstrated robust monotherapy activity in pancreatic ductal adenocarcinoma (PDAC) and KRAS-mutant non-small cell lung cancer (NSCLC), and encouraging initial activity in KRAS-mutant colorectal cancer (CRC) in combination with an anti-EGFR antibody. ERAS-0015 has been generally well-tolerated with favorable safety data and with well-behaved pharmacokinetics (PK). Emerging tolerability data with chemotherapy, pembrolizumab, and panitumumab support combination development at ERAS-0015 doses within the pharmacologically active dose (PAD) range. ERAS-0015 is also designed to inhibit RAS wildtype variants, which may contribute to resistance to mutant-selective approaches. Together, these findings support its potential as both a monotherapy and backbone for combination regimens. 

About ERAS-4001
ERAS-4001 is an investigational, oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile. Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors. Preliminary clinical data have demonstrated favorable safety and tolerability across doses evaluated. Promising preliminary pharmacokinetic (PK) data have been observed. In nonclinical studies, ERAS-4001 showed potent activity against both guanosine triphosphate (GTP)-bound (active state) and GDP-bound (inactive state) KRAS and induced tumor regression in multiple KRAS-mutant models. ERAS-4001 also inhibited wildtype KRAS, which may contribute to resistance to mutant-selective approaches, while sparing wildtype HRAS and NRAS. Preliminary monotherapy antitumor activity supports ERAS-4001’s potential as a combination partner for ERAS-0015.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits for each of our product candidates, including ERAS-0015 and ERAS-4001; the planned advancement of our development pipeline, including the anticipated timing of data readouts for the AURORAS-1 and BOREALIS-1 trials, and our expectations related to the initiation of our clinical trials and patient cohorts; our plans to initiate multiple potentially registration-enabling trials for ERAS-0015 in lung cancer and pancreatic cancer in the time periods set forth in this press release; characterizations of the clinical profile of ERAS-0015 and ERAS-4001; the potential for ERAS-0015 to be used in combination therapies, including in combination with ERAS-4001; the potential for ERAS-0015 to be best-in-class; and the potential for ERAS-4001 to be first-in-class and best-in-class. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: potential delays in the initiation, enrollment, data readout, and completion of clinical trials, including the AURORAS-1 and BOREALIS-1 trials and the planned future trials discussed in this press release; our product candidates, including ERAS-0015 and ERAS-4001, may not demonstrate therapeutic benefits that we expect; interim, topline and preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that an unconfirmed partial response to treatment may not ultimately result in a confirmed partial response to treatment after follow-up evaluations; the limitations of preliminary data based on small patient populations and limited follow-up, and of cross-study comparisons that are not based on head-to-head trials and may not be directly comparable due to differences in study designs, patient populations and assessment methods; FTD may not result in a more expedited development or regulatory review process, and such a designation does not increase the likelihood that ERAS-0015 will receive marketing approval in the United States; our approach to the discovery and development of product candidates is based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; results from preclinical studies not necessarily being predictive of future results; our assumptions around which programs may have a higher probability of success may not be accurate, and we may expend our limited resources to pursue a particular product candidate and/or indication and fail to capitalize on product candidates or indications with greater development or commercial potential; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; our planned potentially registration-enabling trials may be delayed based on FDA feedback or requirements, as the FDA retains broad discretion to require additional clinical data prior to the conduct of a registrational trial or submission for regulatory approval; even if our planned trials are successful, they may not support regulatory approval; the inability to realize any benefits from our current licenses, acquisitions, and collaborations, and any future licenses, acquisitions, or collaborations, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses, including our ability to successfully defend against allegations raised by, or any future litigation initiated by, Revolution Medicines (RevMed) that ERAS-0015 infringes patents held by RevMed or was derived from RevMed trade secrets; the sufficiency of our cash, cash equivalents, and marketable securities; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

Source: Erasca, Inc.

Frontier Minerals consortium to enter exclusive negotiations with Government of Kenya for prospecting licence for Mrima Hill, one of the world’s largest and highest grade rare earth projects,¹ and concurrently pursue potential non-dilutive funding including U.S. Government grant support.

KELLOGG, Idaho, Nov. 20, 2026 (GLOBE NEWSWIRE) — Bunker Hill Silver Corp. (“Bunker Hill” or the “Company”) (TSX: BNKR | OTCQB: BHLL) is pleased to announce that Frontier Minerals LLC (“Frontier”), a U.S.-led consortium which includes Bunker Hill alongside ReElement Technologies Corporation (“ReElement”) and American Resources Corporation (“American Resources”) (NASDAQ: AREC), has received notification from the Government of Kenya’s Ministry of Mining, Blue Economy and Maritime Affairs (the “Ministry”) that it is the successful bidder in the international tender for the exclusive right to negotiate a prospecting licence for the Mrima Hill Rare Earth and Niobium Project in Kwale County, Kenya (“Mrima Hill” or the “Project”). The Cabinet Secretary for Mining, Blue Economy and Maritime Affairs announced the outcome of the tender on November 19, 2026.

Frontier is partnered with Bunker Hill, ReElement and American Resources, bringing together complementary expertise in mineral resource development, critical minerals supply chains and advanced refining technologies. Bunker Hill and the other consortium partners are expected to hold equity interests in Frontier, with the specific terms of the joint venture to be set forth in definitive agreements. Frontier is also pursuing U.S. government funding through the U.S. Department of State’s U.S.-Africa Strategic Investment Program for Project support. Subject to confirmation in definitive agreements, Bunker Hill does not anticipate a material cash outlay from the Company in the near-term or throughout the Mrima Hill feasibility study completion.

Mrima Hill is the first mining project in Kenya to be offered through an open and competitive international tender. Frontier’s proposal combines Bunker Hill’s mine-building and operating capability, as the consortium’s mining and processing partner, with the innovative American refining capabilities and rare earth and critical minerals supply chain relationships contributed by ReElement and American Resources, a model designed to deliver separated rare earth and niobium products refined in Kenya for Western supply chains.

Under the proposed development plan submitted through the tender process, and if the consortium is ultimately awarded a prospecting licence for the Project, Bunker Hill will lead exploration and resource definition, metallurgical test work, process development and the feasibility study, which it will manage. Bunker Hill is also positioned to be contracted by the consortium to build and operate the mine and processing plant for Frontier in accordance with the results of the feasibility study. To maintain the Bunker Hill Mine team’s focus on the commissioning of the Bunker Hill operations in Idaho, the Project exploration, feasibility study, development and operations will be overseen and managed by a dedicated team assembled specifically for Mrima Hill in Kenya.

Bunker Hill will host a conference call and webcast on Monday, November 23, 2026, at 10:00 am Eastern Time. Details are provided below.

Highlights

  • Capital light participation: Bunker Hill expects to hold an equity interest in Frontier, subject to definitive agreements. The Frontier consortium is pursuing potential U.S. government financing for the Project and Bunker Hill does not expect to be required to make material cash contributions through completion of a feasibility study. Subject to confirmation through definitive agreements among the consortium partners, Bunker Hill expects to maintain the right but not the obligation to fund Project development.
  • World-scale, two-metal deposit: Historical 2013 NI 43-101 estimates of 48.7 Mt Indicated at 4.40% Total Rare Earth Oxides (TREO) and 110.7 Mt Inferred at 3.61% TREO (1.0% TREO cut-off), and 47.8 Mt Indicated at 0.66% Nb2O5 and 94.4 Mt Inferred at 0.73% Nb2O5 (0.2% Nb2O5 cut-off)², all from surface (historical estimates; not current mineral resources; see “Historical Mineral Resource Estimates” below).
  • Approximately 7% TREO from surface: Historical estimates include higher-grade domains of 11.2 Mt Indicated at 6.93% TREO and 15.6 Mt Inferred at 7.12% TREO at a 5.8% TREO cut-off².
  • Thick high-grade intercepts and open for expansion: Historical drilling returned 105 m at 6.97% TREO from surface, ending in mineralization and including 35 m at 8.50% TREO². Mineralization is open at depth, with rare earth and niobium mineralization reported more than 100 m below surface, and open to the south at the south-eastern margin of the deposit.
  • Rich in high-value magnet metals: Approximately 21% of the historical Indicated TREO is made up of neodymium, dysprosium, europium, terbium and yttrium oxides, with heavy rare earth enrichment relative to typical carbonatite deposits.
  • Coastal location near East Africa’s largest port: Mrima Hill is approximately 60 km by road from the Port of Mombasa and 10 km from the Indian Ocean coast. The project sits near the Mombasa–Lunga Lunga highway, which connects directly to the port.
  • Strategic U.S. critical minerals: Rare earths and niobium are both on the U.S. 2025 List of Critical Minerals. USGS ranks niobium, dysprosium, terbium, yttrium and gadolinium among the highest-risk minerals on that list. Frontier has proposed, subject to confirmation through the feasibility study, to produce separated products refined in Kenya.
  • Fast-track work program: If awarded the licence, Frontier’s 36-month work program will start with twin and confirmation drilling of the historical holes, with the aim of delivering a current NI 43-101 mineral resource within the first year. Expansion drilling, metallurgical test work and the environmental and social impact assessment follow. Frontier is targeting a feasibility study and a development decision within three years of the licence being issued.
  • Refining technology chosen on the evidence: The feasibility study, managed by Bunker Hill, will include a rigorous trade-off study of refining technologies. Subject to its results, ReElement’s chromatography-based separation technology may be used to refine the Project’s rare earths and niobium in Kenya.
  • Dedicated Mrima Hill Team:  Frontier has assembled a project team with experience on carbonatite rare earth and niobium deposits across Africa, Europe and North America. The Bunker Hill Mine team in Idaho will remain fully focused on ramping up to commercial production at the Bunker Hill Mine.
  • Potential U.S. Government funding: Mrima Hill represents a strategic asset to western governments, Frontier holds established and deep relationships within the U.S. government and has been invited to submit an application for grant funding to the U.S. Department of State.

Management Commentary

Richard Williams, Executive Chairman of Bunker Hill, commented: “Mrima Hill is one of the world’s great undeveloped rare earth deposits, and we are proud to have been chosen to help unlock it. In Idaho we are bringing a mine that had been closed for four decades back into production. We along with our consortium partners are bringing that same capability, and a dedicated team, to Kenya, while the Bunker Hill Mine stays fully focused on ramping up to commercial production. This is a defining step in building Bunker Hill into a leading Western supplier of critical minerals.”

Bradley Barnett, CFO of Bunker Hill and Managing Member of Frontier, added: “Kenya ran the first open and competitive mining tender in its history and set a high bar on beneficiation, transparency and community benefit. Frontier proposed a plan to deliver a current resource within a year and a feasibility study within three, and to refine separated rare earth and niobium products in Kenya. We thank Cabinet Secretary Joho, the Ministry and the people of Kwale County for their confidence. We look forward to working with the communities of Kwale County and the Ministry through the licensing process and getting to work.”

Mark C. Jensen, Chairman and Chief Executive Officer of American Resources and ReElement Technologies, added: “We are proud to partner with Bunker Hill and Frontier Minerals on this significant opportunity. By combining world-class mining expertise with advanced American refining technologies and integrated critical mineral supply-chain capabilities, we believe we can establish a new model for resource development that enables Kenya to capture greater economic value from its mineral resources while strengthening secure supply chains for the United States and its allies. This selection is not the culmination of our efforts, but the beginning of a long-term partnership focused on responsible development, economic opportunity and shared prosperity.”

U.S. Government Support, Strategic Importance and Community Engagement

Frontier is a U.S.-led consortium. Its aim is to build a secure, US-aligned supply of rare earths and niobium. The United States Geological Survey (USGS) ranks niobium, dysprosium, terbium, yttrium and gadolinium among the highest-risk minerals on the U.S. Government’s 2025 list of Critical Minerals. The United States has had no significant niobium mine production since 1959 and imports most of the rare earths it uses. China tightened export controls on rare earth elements in 2025, adding urgency to the search for independent sources. Mrima Hill, with large, high-grade rare earth and niobium mineralization from surface and direct access to a deep-water port, is positioned to become a cornerstone of that supply.

The U.S. Government has made clear its support for developing Kenya’s critical minerals sector. Senior U.S. Department of State officials have publicly backed U.S. participation in the Mrima Hill tender, described the process as transparent, and stated that Washington is ready to help Kenya build a local critical minerals processing industry and become a regional leader in the sector4. Speaking to the American Chamber of Commerce in Kenya in Nairobi on 9 September 2026, Chris Kulukundis, then Acting Deputy Assistant Secretary of State for Southern Africa and Critical Minerals, said: “The Mrima Hill tender process is moving forward in a transparent manner.” Frontier is preparing a full proposal, at the invitation of the U.S. Department of State’s Bureau of African Affairs, under the Department’s publicly announced U.S.-Africa Strategic Investment Program, for Project support. No award has been made, the terms of any award are not known and there is no assurance that funding will be approved.

Bunker Hill and its consortium partners recognize the environmental and cultural significance of Mrima Hill to the Digo community and the people of Kwale County. Working with the Ministry, Frontier intends to engage openly with local communities and stakeholders as the Project advances, and to develop it responsibly and in partnership with the Government of Kenya.

Bunker Hill’s Role

Under the proposed development plan submitted through the tender process Bunker Hill will be the mining and processing partner in Frontier if the consortium is awarded the prospecting licence. It will be responsible for exploration and resource definition, mine planning, metallurgical test work, process development and the feasibility study, which it will manage. ReElement and American Resources contribute innovative American refining capabilities and rare earth and critical minerals supply chain relationships. The feasibility study will include a trade-off study of refining technologies, amongst other standard trade-off studies common in a feasibility study of this type. Subject to a positive feasibility study, the grant of a Mining Licence and financing, Bunker Hill is positioned to be contracted by Frontier to build and then operate the mine and processing plant. Bunker Hill also expects to hold an equity interest in Frontier, subject to definitive agreements.

Dedicated Project Team

Frontier has assembled a team built specifically for Mrima Hill, with extensive experience on carbonatite-hosted deposits, including rare earth and niobium deposits, in the United States, Malawi, Tanzania, South Africa and Angola and Finland as well as in rare earth processing and refining technology. Resident positions, including a resource geologist and environmental and community teams, will be recruited in Kenya before the program starts.

Bunker Hill’s leadership will provide strategic oversight. Sam Ash will oversee the mining engineering work, Richard Williams will advise the Steering Committee, and Bradley Barnett will serve on the Steering Committee. The Project will be delivered by its own dedicated team, keeping the Bunker Hill Mine’s management and operating team fully focused on the ramp-up to commercial production in Idaho.

The Mrima Hill Deposit

Mrima Hill is a carbonatite complex located approximately 60 km south-west of Mombasa, capped by a thick residual (laterite) profile enriched in rare earth phosphates and pyrochlore-hosted niobium. The rare earth suite includes the high-value magnet rare earths neodymium, praseodymium, dysprosium and terbium. Because the enrichment is in the residual cap, mineralization starts at surface: 83% of the tonnage in the 2011 historical estimate lay within 20 metres of surface.

The 2013 historical estimates² are modelled over a 1,500 m by 900 m footprint to 250 m depth. Drilling by Pacific Wildcat Resources Corp. (“PAW”) between 2011 and 2013 returned intercepts including 105 m at 6.97% TREO from surface, ending in mineralization and including 35 m at 8.50% TREO, and reported rare earth and niobium mineralization extending more than 100 m below surface. The deposit is open at depth and to the south. Mrima Hill has been ranked among the world’s largest rare earth projects by contained TREO¹, with grades that compare favourably with the few rare earth deposits in production or at feasibility outside China.

Seventy Years of Technical Work

Mrima Hill has been recognized as a rare earth and niobium occurrence since the 1930s, and has drawn sustained interest from major mining companies and government agencies ever since. Between 1955 and 1957, Anglo American completed approximately 1,100 m of drilling, 424 test pits, five prospect shafts and a 172 m adit. Pechiney Saint-Gobain explored the rare earths from 1967 to 1971, processing a 42-tonne bulk sample grading approximately 12% REO through its La Rochelle pilot plant to produce a 23% REO concentrate by grinding and classification alone³. The Geological Survey of Kenya, a Japanese-Kenyan joint venture and the USGS all reported on the deposit between 1959 and 19985. Between 2010 and 2012, PAW drilled 98 holes totaling approximately 7,700 m, 69 of which (5,062 m) support the 2013 historical estimates. PAW also completed the 2011 and 2013 NI 43-101 historical estimates and bench-scale leach test work, and received environmental approval for its project in 2013. Most recently, in 2022, the Government of Kenya completed a geological survey of Mrima Hill.

Historical Mineral Resource Estimates

Category Cut-off Tonnes (Mt) Grade Contained
Total Rare Earth Oxides (TREO)
Indicated 1.0% TREO 48.7 4.40% TREO 2.15 Mt TREO
Inferred 1.0% TREO 110.7 3.61% TREO 4.00 Mt TREO
Including high-grade domain – Indicated 5.8% TREO 11.2 6.93% TREO 0.78 Mt TREO
Including high-grade domain – Inferred 5.8% TREO 15.6 7.12% TREO 1.11 Mt TREO
Niobium (Nb2O5)
Indicated 0.2% Nb2O5 47.8 0.66% Nb2O5 699 Mlb Nb2O5
Inferred 0.2% Nb2O5 94.4 0.73% Nb2O5 1,525 Mlb Nb2O5


Source: PAW news release, 29 July 2013; effective date 25 July 2013. TREO includes yttrium oxide. The high-grade domains are included within, and are not additional to, the 1.0% TREO cut-off estimates. Indicated and Inferred estimates are reported separately and are not additive. These are historical estimates; Bunker Hill is not treating them as current mineral resources.

The mineral resource estimates referred to in this news release are historical estimates within the meaning of NI 43-101. They were prepared for Pacific Wildcat Resources Corp. (“PAW”) and are reported in PAW’s news release dated 29 July 2013 titled “High Grade and Large Tonnage Niobium and Rare Earth Resource for Mrima Hill” (effective date of the estimate 25 July 2013; Qualified Person Benjamin C. Pollard of BMGS Perth Pty Ltd). They use the Indicated and Inferred categories of the CIM Definition Standards (2010). They are based on 55 reverse-circulation holes (3,413 m) and 14 diamond holes (1,649 m), modeled by ordinary kriging, reported above cut-off grades of 1.0% TREO (TREO includes Y2O3) and 0.2% Nb2O5, and constrained to the boundary of the former Special Mining Licence 351. No pit-shell or other economic constraint was applied. The Company considers the estimates relevant as an indication of the mineralization at Mrima Hill, but their reliability cannot be confirmed until the underlying drilling, sampling, assay and QA/QC data have been obtained and verified. The Company is not aware of any more recent estimate. To verify the historical estimates or upgrade them to current mineral resources, the Company would need to obtain and verify the historical database, re-assay retained material where available, carry out confirmatory and infill drilling and density work, update the geological model, and assess reasonable prospects for eventual economic extraction, including the protected status of the Mrima Hill forest block. A qualified person has not done sufficient work to classify the historical estimates as current mineral resources or mineral reserves, and the Company is not treating them as current mineral resources or mineral reserves. These historical estimates were not prepared under S-K 1300.

Bunker Hill considers these estimates to be relevant as an indication of the scale and grade of the mineralization at Mrima Hill and reliable in that they were prepared by independent qualified persons under NI 43-101 from drilling completed to industry standards at the time. However, a qualified person acting for the consortium has not done sufficient work to classify the historical estimates as current mineral resources or mineral reserves, Bunker Hill is not treating the historical estimates as current mineral resources or mineral reserves, and the historical estimates should not be relied upon. Bunker Hill does not yet have access to the drill-hole database, assay certificates, sample material or drill core supporting the historical estimates. To verify and upgrade the historical estimates to current mineral resources, Bunker Hill would need to obtain and audit the historical data, complete twin and confirmatory drilling with current QA/QC, update the geological model and density data and have an independent qualified person prepare a new estimate, all of which form part of the consortium’s planned work program. Bunker Hill is not aware of any more recent mineral resource estimate for Mrima Hill.

Next Steps and Work Program

The Ministry has stated that the award is not a licence. Before any prospecting begins, Frontier must engage openly and respectfully with host communities, landowners, county leadership and local stakeholders and obtain the consents required under Kenya’s Mining Act; apply for a prospecting licence through the Ministry’s Online Mining Cadastre; and have that application reviewed by the Mineral Rights Board, on whose recommendation the Cabinet Secretary grants the licence. Alongside that process, Frontier will also seek access to the historical drill database and core, and start recruiting its in-country team, including a resident resource geologist and environmental and community specialists.

If the Prospecting Licence is issued, Frontier will begin a 36-month work program. The first phase twins and confirms the historical PAW drill holes and is designed to deliver a current NI 43-101 mineral resource estimate within the first year. The second phase will define the broader extent of the deposit. Metallurgical test work and process development will run alongside the drilling, including a planned metallurgical testing and pilot facility in Kenya and the refining technology trade-off study, in which ReElement’s chromatography-based separation technology will be assessed. The program also includes a feasibility study and an environmental, social and health impact assessment (“ESHIA”), with a radiological baseline and radiation safety management plan, and is designed to deliver a development decision within three years of licence issue.

Conference Call and Webcast

Bunker Hill will host a conference call and webcast to discuss the Mrima Hill selection and Frontier partnership on November 23, 2026, commencing at 10:00 a.m. Toronto / 8:00 a.m. Vancouver / 7:00 a.m. Kellogg.

Conference Call Details
Toll-free in U.S. and Canada: 1-844-763-8274
International Callers: +1-647-361-0247

Webcast Details
Participants may join the webcast by registering at the link below:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=ry1HA0yZ

Qualified Person

The scientific and technical information in this news release has been reviewed and approved by Scott Wilson, C.P.G., SME-RM, President of Resource Development Associates, Inc., a qualified person as defined by NI 43-101 and independent of Bunker Hill. Mr. Wilson has not verified the historical data underlying the Mrima Hill estimates, including drilling, sampling, assay and QA/QC data.

About Bunker Hill Silver Corp.

Bunker Hill Silver Corp. is a U.S.-focused mining company building a modern, long-life operation at its flagship Bunker Hill Mine in northern Idaho’s prolific Silver Valley, complemented by a pipeline of high-grade silver development projects across North America. With production now underway, the Company is advancing the Bunker Hill Mine toward commercial production of zinc, lead and silver concentrates while pursuing opportunities to optimize operations, expand resources and extend mine life.

The Bunker Hill Mine sits in one of North America’s most abundant and storied mining districts and benefits from established infrastructure, a skilled local workforce and a significant mineral resource base. Through its acquisition of Silver47 Exploration Corp., Bunker Hill has added a portfolio of silver-rich projects in Alaska, Nevada and New Mexico, anchoring the Company in America’s most prolific mining jurisdictions.

Bunker Hill’s strategy is focused on disciplined operational execution, responsible mining practices and continued investment in its assets to deliver sustainable production, organic growth and long-term shareholder value.

For More Information

Giordy Belfiore, Vice President, Investor Relations

(604)288-8004 | IR@bunkerhillmining.com

www.bunkerhillsilver.com

References

¹ Ranked fourth-largest rare earth project globally by contained TREO, “RANKED: World’s top 10 rare earth projects,” MINING.COM / Mining Intelligence, June 2023. Grade comparison based on publicly reported mineral resource estimates: Mount Weld 106.6 Mt at 4.12% TREO (Lynas, August 2024); Araxá 70.91 Mt at 4.06% TREO (St George Mining, March 2026); Kangankunde 261 Mt at 2.19% TREO (Lindian Resources, 2023); Kvanefjeld 1,010 Mt at 1.1% TREO (SRK, 2015).

² Historical estimates prepared for Pacific Wildcat Resources Corp. (“PAW”) by Benjamin C. Pollard, BMGS Perth Pty Ltd (Qualified Person), effective 25 July 2013, as reported in PAW’s news release dated 29 July 2013, “High Grade and Large Tonnage Niobium and Rare Earth Resource for Mrima Hill”. TREO cut-off 1.0%; Nb2O5 cut-off 0.2%. A qualified person has not done sufficient work to classify the historical estimates as current mineral resources, and Bunker Hill is not treating them as current mineral resources.

³ Pechiney Saint-Gobain pilot-plant test work, La Rochelle, France (1971), as summarized in “NI 43-101 Technical Report for the Initial Niobium Resource Estimate, Mrima Hill Rare Earth/Niobium Project in Southern Kenya,” Sound Mining Solution (Pty) Ltd, Report SMS/027/11, dated 15 August 2011, filed on SEDAR+ under Pacific Wildcat Resources Corp.’s issuer profile. These results are historical, and Bunker Hill has not verified them.

⁴ Statements by Frank Garcia, U.S. Assistant Secretary of State for African Affairs, and Chris Kulukundis, Acting Deputy Assistant Secretary of State for Southern Africa and Critical Minerals, as reported in “US says it will help develop Kenya’s critical minerals processing,” Mining Weekly, 10 September 2026.

⁵ Exploration history as summarized in the Sound Mining Solution technical report dated 15 August 2011 (SEDAR+) and in PAW public disclosure. These results are historical, and Bunker Hill has not verified them.

Cautionary Statements

Certain statements in this news release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, as well as within the meaning of the phrase “forward-looking information” in the Canadian Securities Administrators’ National Instrument 51-102 – Continuous Disclosure Obligations (collectively, “forward-looking statements”). Forward-looking statements are not comprised of historical facts. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, “plan” or variations of such words and phrases. Forward-looking statements in this news release include, but are not limited to, statements regarding: the completion of the award process, the outcome and timing of community consents and the licensing process in Kenya and the grant of a Prospecting Licence and any subsequent Mining Licence; the planned work program and its timing, including the timing of a feasibility study and potential development decision; the potential to establish current mineral resources at Mrima Hill; the amenability of the mineralization to processing; the refining technology trade-off study and the potential use of ReElement’s technology; the establishment of metallurgical testing, pilot and refining facilities in Kenya; Bunker Hill’s expected role in the construction and operation of a mine and processing plant and Bunker Hill’s economic participation in the project; the composition and availability of the Project team; the availability of funding for the Project, including any U.S. Government grant; community and stakeholder agreements; and the ramp-up of the Bunker Hill Mine to commercial production.

Factors that could cause actual results to differ materially include, among others: the award not being finalized, or community consents and licences not being obtained on acceptable terms or at all; licence terms, community agreements, environmental, forest-reserve and cultural-heritage approvals, or funding not being obtained; the historical estimates not being confirmed; thorium and radiological conditions; political, regulatory and legal risks in Kenya; metallurgical and processing risks; commodity price volatility; and the other risks described in the Company’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov).

Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, undue reliance should not be placed on such statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, other than as required by law.

Historical estimates referenced in this news release are not current mineral resources and the Company is not treating them as such.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company’s new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of November 16, 2026, and consist of a non-statutory stock option award to purchase up to 200,000 shares of Ocular’s common stock and a restricted stock unit award representing the right to receive 65,000 shares of Ocular’s common stock. The stock option award has an exercise price of $6.01 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. The stock option award has a ten-year term and vests over four years, with 25% of the original number of shares subject to the award vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. The restricted stock unit award vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR). Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

WeRide Inc. Announces Unaudited Financial Results for the Third Quarter of 2026

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD; HKEX: 0800), a global leader in autonomous driving technology, today announced its unaudited financial results for the third quarter ended September 30, 2026.

Operational and Financial Highlights

  • Revenue grew 88.0% and gross margin expanded to 43.0%, driven primarily by the overseas business. Total revenue for the third quarter of 2026 was RMB321.5 million (US$48.0 million), representing an increase of 88.0% year over year and 38.8% quarter over quarter. Gross margin reached 43.0%, up 10.1 percentage points year over year. Revenue from higher-margin overseas operations was RMB146.9 million (US$21.9 million), up 171.5% year over year, and accounted for 45.7% of total revenue.
  • AI Infrastructure revenue nearly doubled, capturing fast-growing data demand from Physical AI. Leveraging the closed‑loop data capabilities built over years of autonomous‑driving operations, Jingshuo Technology, WeRide’s Physical AI Infrastructure (“AI Infrastructure”) subsidiary, serves customers across embodied AI, robotics, autonomous driving and foundation models, with end‑to‑end solutions spanning pre‑training data, post‑training environments and trusted verification. Driven by surging demand for high-quality physical-world data, revenue from this business nearly doubled year over year.
  • Quarterly Robotaxi revenue surpassed RMB100 million; Guangzhou operations achieved positive unit economics. In the third quarter of 2026, Robotaxi revenue exceeded RMB100 million for the first time, up 204.0% year over year, with overseas markets contributing more than 90% of total Robotaxi revenue. The Company’s Robotaxi operations in Guangzhou achieved positive unit economics, marking an important milestone in validating the economics of Robotaxi operations at scale.
  • Global L4 fleet of approximately 4,100 vehicles; Robotaxi fleet up 26% quarter over quarter. As of October 31, 2026, the Company’s global L4 fleet comprised approximately 4,100 vehicles, including more than 2,300 Robotaxis. The Robotaxi fleet increased by 26% quarter over quarter.
  • WeRide secured Spain’s first national operating permit for L4 autonomous passenger vehicles, accelerating commercialization in Europe. The Company received Spain’s first L4 autonomous passenger vehicle operating permit from the Spanish Directorate-General for Traffic (“DGT”), laying the groundwork for commercial services in Spain. The Company also advanced its operations in Switzerland, Belgium and France, and began road testing in Slovakia, while continuing to expand its collaboration with local public transportation operators.
  • Asset-light expansion accelerating in the Middle East, with a fleet of approximately 600 vehicles. The Company continues to expand its operating fleet and service areas in the Middle East, targeting full coverage of the core urban areas of Abu Dhabi and Dubai by year-end. The Company’s Middle East fleet reached approximately 600 vehicles, up approximately 50% from about 400 vehicles as of July 31, 2026. As of the date of this release, WeRide is Uber’s largest autonomous vehicle partner outside the United States, measured by the number of fully driverless Robotaxis operating on its platform.
  • L2++/L3 mass production accelerating, with cumulative WRD 3.0 deliveries exceeding 100,000 units. Now, the AION i60, GAC Trumpchi Yue 7 and AION Ray7, all equipped with the Company’s WRD 3.0 one-stage end-to-end L2++/L3 solution, were launched, extending the solution’s adoption across more production models and driving scenarios. By the end of the quarter, cumulative deliveries of WRD 3.0 exceeded 100,000 units. The Company continued to expand its partnership network, establishing collaborations with several leading OEM groups.

L4 Business Update

Robotaxi Business Update

In the third quarter of 2026, Robotaxi revenue exceeded RMB100 million for the first time, representing an increase of 204.0% year over year, with overseas markets contributing more than 90% of total Robotaxi revenue.

International Operations

  • Overseas Robotaxi revenue grew rapidly, supported by the Company’s high-margin, asset-light business model. In overseas markets, the Company provides autonomous driving technology and remote assistance, while local partners provide fleet investment and handle other operations. This division of roles enables the Company to continue scaling deployments across Europe and the Middle East with greater capital efficiency.
  • The Middle East fleet expanded, with broader coverage of core urban areas. The Company continued to expand its Middle East fleet to approximately 600 Robotaxis and extend its operating areas in Abu Dhabi and Dubai, now covering the major districts of both cities’ core urban areas. This lays the foundation for broader service coverage and future operational growth.
  • WeRide obtained Spain’s first national L4 autonomous driving permit and advanced its Madrid deployment. In September 2026, the Company, together with Uber and AVOMO, received Spain’s first L4 autonomous passenger vehicle operating permit from the DGT, allowing vehicles to be deployed on public roads. The permit authorizes testing of WeRide’s GXR autonomous vehicles in Spain and marks the beginning of mapping in the Madrid region ahead of the Company’s first joint launch in Europe.
  • L4 deployments and services in Switzerland and Slovakia continued to advance. Along with its partners, Schweizerische Bundesbahnen (“SBB”) and Swiss Transit Lab (“STL”), the Company launched public Robotaxi services in Canton of Zurich. In Slovakia, the first batch of Robotaxis began road testing, building operating experience to support future deployments.
  • Robotaxi services in Asia continued to expand. In Singapore, the Company continued to expand its Robotaxi service together with Grab and had provided more than 20,000 L4 autonomous driving rides as of the end of the third quarter of 2026.

China Operations

  • Guangzhou operations achieved positive unit economics, with further improvements in operational efficiency. In the third quarter of 2026, domestic Robotaxi operations achieved an average of 21 daily orders per vehicle, with a peak of 33 orders per vehicle in one day. Cumulative registered users continued to grow rapidly, up 143.5% from the end of the previous quarter.
  • Service areas in key cities continued to expand. In Guangzhou, the Company’s Robotaxi service covers Tianhe, Haizhu and the core districts of Huangpu. These developments provide a solid foundation for further scaling the Company’s Robotaxi business.

Other L4 Business Updates

  • Robobus achieved one of Europe’s first fully driverless services. At Zurich Airport, the Company’s Robobus now operates without an onboard safety operator, making it one of the first fully driverless Robobus services in Europe. The Company is also advancing autonomous driving collaborations with public transportation operators such as Keolis in France and expanding its Robobus operations in Belgium. In Slovakia, the Robobus fleet has arrived and commenced testing.
  • Robosweeper expanded its presence in Singapore. The Company has partnered with leading environmental services providers, Chye Thiam Maintenance and RE Sustainability, to deliver sanitation services across key locations including Marina Coastal Drive, the Esplanade and Sentosa Island, with further deployments expected in the near term.

L2++/L3 Business Update

  • Cumulative deliveries exceeded 100,000 units, with a growing mass-production pipeline. As of the end of the quarter, cumulative deliveries of the Company’s WRD 3.0 L2++/L3 solution exceeded 100,000 units. During the quarter, the Company secured 10 new L2++/L3 mass-production design wins, further expanding its pipeline of future production programs.
  • Customer base and design-win portfolio continued to expand. The Company secured multiple new design wins from several leading OEMs, further validating the competitiveness of its technology and expanding its customer reach.
  • The Company’s L2++/L3 solution continued to demonstrate its capabilities in driving competitions. Customer vehicles equipped with the Company’s L2++/L3 solution have won eight championships in the China Intelligent Driving Competition, further demonstrating the solution’s overall technical capabilities.

AI Infrastructure Business Update

High-quality real-world data and verifiable training environments are key enablers for the development of Physical AI foundation models.

  • End-to-end capabilities covering the full path from pre-training to continuous learning. Building on the closed-loop data capabilities developed through the Company’s autonomous driving operations, Jingshuo provides pre-training data, post-training environments and trusted verification across the full path from pre-training to continuous learning. Its capabilities span data collection, quality control and annotation, synthetic data generation, environment construction, independent evaluation and post-training integration. It offers high-quality datasets, licensing of data-processing software and post-training environments, and customized data services to customers in autonomous driving, foundation models, embodied AI and robotics.
  • A three-layer product suite and two engines, closing the “collection–assetization–training” loop.  Jingshuo’s product stack comprises three layers. EGOK is a proprietary wearable multimodal collection terminal with hardware-level synchronization. SkillForge turns first-person operation data into trainable, verifiable and licensable skill assets with task definitions and success criteria. Crucible is an environment hub that connects tasks into executable, independently judged environments and supports post-training integration. Two engines connect the layers: the Data Engine turns experience into versioned data and skills, and the World Engine, powered by the GENESIS-Robotics world model, turns real-world demonstrations into verifiable training environments.
  • High-quality multimodal data assets support applications across diverse real-world scenarios. Through automated 3D reconstruction, multimodal alignment and fine-grained annotation, Jingshuo has built a large-scale dataset library serving foundation model, embodied AI and robotics customers in China and overseas.

Management Commentary

Tony Han, WeRide’s Founder, Chairman, and Chief Executive Officer, stated, “This quarter showed that our global strategy is working. Overseas markets now generate nearly half of our total revenue and more than 90% of our Robotaxi revenue. Operating driverless fleets in foreign markets is challenging, which is exactly why it is becoming our long-term moat. With new deployments in Europe and a Middle East fleet of approximately 600 vehicles, WeRide is now Uber’s largest autonomous vehicle partner outside the United States by driverless fleet size. In China, our Guangzhou Robotaxi operations achieved positive unit economics, demonstrating that Robotaxi can be a sustainable business. Robotaxi is our core business and the fastest path to commercializing Physical AI. The technology and closed-loop data we have built on real roads now power three mutually reinforcing businesses: Robotaxi, L2++/L3 solutions, and AI Infrastructure, which extends these capabilities to foundation models, embodied AI and robotics. As an infrastructure builder for Physical AI, we are just getting started.”

Jennifer Li, WeRide’s Chief Financial Officer and Head of International, added, “This quarter, revenue grew by 88% to RMB321.5 million, gross margin reached 43%, and overseas revenue made up nearly half of the total. Our asset-light model enables us to expand quickly and efficiently. Based on our operating plan, we have more than four years of cash runway, sufficient to fully fund our path to self-sustaining cash flow. More importantly, we are building a long-term moat. Operating across 13 countries and holding permits in 9 requires years of regulatory trust and operational experience — this is hard to replicate. We will translate this lead into sustainable, profitable growth.”

Third Quarter 2026 Financial Results

Revenue

Total revenue grew 88.0% year over year to RMB321.5 million (US$48.0 million) in the third quarter of 2026, compared with RMB171.0 million in the same period of 2025. The increase was primarily driven by the expansion of the Company’s Robotaxi-centered L4 business, rapid growth in the L2++/L3 business and continued growth in the AI Infrastructure business.

Cost of Revenue

Cost of revenue was RMB183.4 million (US$27.4 million) in the third quarter of 2026, compared with RMB114.7 million in the same period of 2025. The increase in cost of revenue was in line with revenue growth in the Robotaxi-centered L4 business and the AI Infrastructure business.

Gross Profit and Gross Margin

Gross profit was RMB138.1 million (US$20.6 million) in the third quarter of 2026, compared with RMB56.3 million in the same period of 2025. Gross margin was 43.0% in the third quarter of 2026, compared with 32.9% in the same period of 2025. Gross margin expansion was mainly driven by revenue growth in the high-margin overseas business and the L2++/L3 business.

Operating Expenses

Operating expenses were RMB505.7 million (US$75.4 million) in the third quarter of 2026, compared with RMB435.8 million in the same period of 2025.

  • R&D expenses were RMB465.3 million (US$69.4 million) in the third quarter of 2026, compared with RMB316.4 million in the same period of 2025. The increase in R&D expenses was primarily due to the increase in personnel and outsourcing labor costs, outsourced R&D expenses and cloud service fees. In addition, from July 1, 2026, the estimated useful lives of IDC-related equipment were uniformly extended to six years, resulting in lower depreciation and amortization expenses.
     
  • Administrative expenses were RMB13.9 million (US$2.1 million) in the third quarter of 2026, compared with RMB100.4 million in the same period of 2025. The significant decrease in administrative expenses was primarily due to a reversal of share-based compensation expenses resulting from employee departures, and a decrease in professional service fees, as the same period of 2025 included fees related to the global offering.
     
  • Selling expenses were RMB26.5 million (US$4.0 million) in the third quarter of 2026, compared with RMB19.0 million in the same period of 2025. The increase in selling expenses was primarily due to the increase in sales personnel costs.

Loss for the Period

  • Loss for the period was RMB310.0 million (US$46.2 million) in the third quarter of 2026, compared with RMB307.3 million in the same period of 2025.
  • Non-IFRS adjusted loss1 for the period was RMB336.5 million (US$50.2 million) in the third quarter of 2026, compared with RMB275.6 million in the same period of 2025.

Earnings Before Interest, Taxes, Depreciation, and Amortization (“EBITDA”)2

EBITDA was negative RMB246.4 million (US$36.7 million) in the third quarter of 2026, an improvement of 2.9% from negative RMB253.7 million in the same period of 2025.

Basic and Diluted Loss per Ordinary Share and per ADS3  

  • Basic and diluted loss per ordinary share was RMB0.32 (US$0.05) in the third quarter of 2026, compared with RMB0.34 in the same period of 2025.
     
  • Basic and diluted loss per ADS was RMB0.96 (US$0.15) in the third quarter of 2026, compared with RMB1.02 in the same period of 2025.

____________________________
1 Non-IFRS adjusted loss for the period is defined as loss for the period excluding share-based compensation expenses and fair value changes of financial assets at FVTPL.
2 EBITDA is defined as loss for the period excluding income tax, finance costs and depreciation and amortization expenses.
3 Each ADS represents three Class A ordinary shares.

Balance Sheet

As of September 30, 2026, WeRide held RMB3,846.5 million (US$573.7 million) in cash and cash equivalents and time deposits, RMB797.7 million (US$119.0 million) in investments in wealth management products, which were recorded in current financial assets at FVTPL, and RMB18.8 million (US$2.8 million) in restricted cash, for an aggregate amount of RMB4,663.0 million (US$695.5 million).

Exchange Rate Information

This announcement contains translations of certain Renminbi (“RMB”) amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to US$ were made at a rate of RMB6.7045 to US$1.00, the exchange rate in effect as of September 30, 2026, as set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System. The Company makes no representation that any RMB or US$ amounts could have been, or could be, converted into US$ or RMB, as the case may be, at any particular rate, or at all.

Use of Non-IFRS Financial Measures

In evaluating its business, the Company considers and uses the non-IFRS financial measures of (i) adjusted loss for the period and (ii) EBITDA as supplemental measures to review and assess operating performance. The Company believes that adjusted loss for the period and EBITDA provide useful information to investors and others in understanding and evaluating the Company’s consolidated results of operations in the same manner as it helps the Company’s management. The Company defines adjusted loss for the period as loss for the period excluding share-based compensation expenses and fair value changes of financial assets at FVTPL. The Company defines EBITDA as loss for the period excluding income tax, finance costs, depreciation and amortization expenses.

The Company presents the non-IFRS financial measures because they are used by its management to evaluate its operating performance and formulate business plans. Adjusted loss for the period enables the Company’s management to assess the Company’s operating results without considering the impact of the aforementioned non-cash adjustment items that it does not consider to be indicative of its core operations. EBITDA enables the Company’s management to assess the Company’s operating results without considering the impact of income tax, finance costs, and depreciation and amortization, and to focus more on operating cash items. Accordingly, the Company believes that the use of these non-IFRS financial measures provides useful information to investors and others in understanding and evaluating its operating results in the same manner as its management and board of directors.

These non-IFRS financial measures are not defined under IFRS and are not presented in accordance with IFRS. The non-IFRS financial measures have limitations as analytical tools. One of the key limitations of using the non-IFRS financial measures is that they do not reflect all items of expenses that affect the Company’s operations. Further, these non-IFRS measures may differ from the non-IFRS information used by other companies, including peer companies, and therefore the comparability may be limited.

The non-IFRS financial measures should not be considered in isolation or construed as alternatives to loss for the period or any other measure of performance information prepared and presented in accordance with IFRS or as an indicator of the Company’s operating performance. Investors are encouraged to review the Company’s historical non-IFRS financial measures in light of the most directly comparable IFRS measures, as shown below. The non-IFRS financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting the usefulness of such measures when analyzing the Company’s data comparatively. You are encouraged to review the Company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the SEC. All information provided in this press release is as of the date of this press release, and WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contacts

Investor inquiries: ir@weride.ai
Press inquiries: pr@weride.ai

Piacente Financial Communications
E-mail: weride@thepiacentegroup.com

   
WeRide Inc.

Unaudited Condensed Consolidated Statements of Financial Position

  As of
  September 30,
2026
  September 30,
2026
  December 31,
2025
  RMB’000   US$’000   RMB’000
ASSETS
         
Non-current assets          
Property and equipment 712,295   106,241   378,769
Right-of-use assets 159,038   23,721   65,870
Intangible assets 15,858   2,365   17,966
Goodwill 44,758   6,676   44,758
Restricted cash – non-current 7,515   1,121   6,487
Financial assets at FVTPL – non-current 391,569   58,404   188,083
Other non-current assets 26,436   3,943   23,668
           
Total non-current assets 1,357,469   202,471   725,601
           
Current assets          
Inventories 501,290   74,769   321,021
Contract assets 22,867   3,411   23,305
Trade receivables 588,472   87,773   462,135
Prepayments and other receivables 449,994   67,118   269,986
Prepayments to and amount due from          
related parties 12,161   1,814   9,010
Financial assets at FVTPL – current 797,731   118,984   144,252
Time deposits 1,237,906   184,638   301,401
Restricted cash – current 11,249   1,678   12,910
Cash and cash equivalents 2,608,606   389,083   6,666,304
           
Total current assets 6,230,276   929,268   8,210,324
           
Total assets 7,587,745   1,131,739   8,935,925
           
EQUITY          
Total equity 6,028,684   899,199   7,900,174

 

   
WeRide Inc.

Unaudited Condensed Consolidated Statements of Financial Position (Continued)

  As of
  September 30,
2026
  September 30,
2026
  December 31,
2025
  RMB’000   US$’000   RMB’000
LIABILITIES
         
Non-current liabilities          
Lease liabilities – non-current 112,335   16,755   23,241
Deferred tax liabilities 2,741   409   3,489
Other non-current liabilities 24,832   3,704   7,720
           
Total non-current liabilities 139,908   20,868   34,450
           
Current liabilities          
Short-term bank loans 613,701   91,536   324,263
Trade payables 237,794   35,468   163,000
Other payables, deposits received and          
accrued expenses 446,401   66,582   408,357
Contract liabilities 39,442   5,883   28,512
Lease liabilities – current 42,452   6,332   31,920
Amounts due to related parties 7,682   1,146   1,949
Put option liabilities 31,681   4,725   43,300
           
Total current liabilities 1,419,153   211,672   1,001,301
           
Total liabilities 1,559,061   232,540   1,035,751
           
Total equity and liabilities 7,587,745   1,131,739   8,935,925

 

       
WeRide Inc.

Unaudited Condensed Consolidated Statements of Profit or Loss
       
  Nine Months Ended September 30,   Three Months Ended September 30,
  2026     2025     2026     2025  
  RMB’000    US$’000    RMB’000    RMB’000    US$’000    RMB’000 
                       
Revenue                      
Product revenue 248,880     37,121     148,466     136,097     20,299     79,185  
Service revenue 418,476     62,418     222,131     185,402     27,654     91,797  
  667,356     99,539     370,597     321,499     47,953     170,982  
Cost of revenue(b)                      
Cost of goods sold (156,852 )   (23,395 )   (89,715 )   (81,274 )   (12,122 )   (54,254 )
Cost of services (245,928 )   (36,681 )   (163,524 )   (102,122 )   (15,232 )   (60,429 )
  (402,780 )   (60,076 )   (253,239 )   (183,396 )   (27,354 )   (114,683 )
                       
Gross profit 264,576     39,463     117,358     138,103     20,599     56,299  
                       
Research and development expenses(a)(b) (1,262,916 )   (188,368 )   (961,003 )   (465,262 )   (69,395 )   (316,368 )
Selling expenses(a)(b) (78,379 )   (11,691 )   (46,804 )   (26,488 )   (3,951 )   (19,024 )
Administrative expenses(a)(b) (165,998 )   (24,759 )   (379,309 )   (13,932 )   (2,078 )   (100,367 )
Other net income 60,269     8,989     5,710     37,657     5,617     2,689  
Impairment loss on receivables and contract assets (3,312 )   (494 )   (5,542 )   (2,928 )   (437 )   (2,742 )
Operating loss (1,185,760 )   (176,860 )   (1,269,590 )   (332,850 )   (49,645 )   (379,513 )
                       
Net foreign exchange (loss)/gain (39,014 )   (5,819 )   8,151     (14,525 )   (2,166 )   2,522  
Interest income 137,087     20,447     126,428     38,581     5,754     51,482  
Fair value changes of financial assets at FVTPL 263     39     46,914     6,172     921     23,760  
Finance costs (9,147 )   (1,364 )   (7,272 )   (4,058 )   (605 )   (3,980 )
Loss before taxation (1,096,571 )   (163,557 )   (1,095,369 )   (306,680 )   (45,741 )   (305,729 )
                       
Income tax (3,194 )   (476 )   (3,405 )   (3,335 )   (497 )   (1,528 )
Loss for the period (1,099,765 )   (164,033 )   (1,098,774 )   (310,015 )   (46,238 )   (307,257 )
Loss attributable to ordinary shareholders of the Company (1,099,765 )   (164,033 )   (1,098,774 )   (310,015 )   (46,238 )   (307,257 )
                       
Loss per ordinary share                      
Basic and diluted loss per Class A and Class B ordinary share (1.11 )   (0.17 )   (1.21 )   (0.32 )   (0.05 )   (0.34 )
Loss per ADS                      
Basic and diluted loss per ADS (3.33 )   (0.51 )   (3.63 )   (0.96 )   (0.15 )   (1.02 )

Note:

(a)     Includes share-based compensation expenses as follows:

       
  Nine Months Ended September 30,   Three Months Ended September 30,
  2026     2025     2026     2025  
  RMB’000    US$’000    RMB’000    RMB’000    US$’000    RMB’000 
Research and development expenses (108,764 )   (16,223 )   (115,243 )   (29,383 )   (4,383 )   (28,857 )
Administrative expenses 12,130     1,809     (155,754 )   49,355     7,361     (26,340 )
Selling expenses (2,214 )   (330 )   (3,951 )   390     58     (229 )
Total share-based compensation expenses (98,848 )   (14,744 )   (274,948 )   20,362     3,036     (55,426 )

(b)     Includes depreciation and amortization expenses as follows:

  Nine Months Ended September 30,   Three Months Ended September 30,
  2026     2025     2026     2025  
  RMB’000    US$’000    RMB’000    RMB’000    US$’000    RMB’000 
Cost of revenue (7,864 )   (1,173 )   (7,611 )   (3,149 )   (470 )   (3,635 )
Research and development expenses (142,950 )   (21,322 )   (94,838 )   (45,827 )   (6,835 )   (38,496 )
Administrative expenses (20,766 )   (3,097 )   (16,811 )   (6,427 )   (959 )   (5,177 )
Selling expenses (2,482 )   (370 )   (1,803 )   (846 )   (126 )   (728 )
Total depreciation and amortization expenses (174,062 )   (25,962 )   (121,063 )   (56,249 )   (8,390 )   (48,036 )

 

WeRide Inc.

Reconciliation of IFRS Measures to Non-IFRS Measures
       
The table below sets forth a reconciliation of loss for the period to non-IFRS adjusted loss for the periods indicated:
       
  Nine Months Ended September 30,   Three Months Ended September 30,
  2026     2025     2026     2025  
  RMB’000    US$’000    RMB’000    RMB’000    US$’000    RMB’000 
Loss for the period (1,099,765 )   (164,033 )   (1,098,774 )   (310,015 )   (46,238 )   (307,257 )
Add:                      
Share-based compensation expenses 98,848     14,744     274,948     (20,362 )   (3,036 )   55,426  
Fair value changes of financial assets at FVTPL (263 )   (39 )   (46,914 )   (6,172 )   (921 )   (23,760 )
Adjusted loss for the period (1,001,180 )   (149,328 )   (870,740 )   (336,549 )   (50,195 )   (275,591 )

The table below sets forth a reconciliation of loss for the period to EBITDA indicated:

  Nine Months Ended September 30,   Three Months Ended September 30,
  2026     2025     2026     2025  
  RMB’000    US$’000    RMB’000    RMB’000    US$’000    RMB’000 
Loss for the period (1,099,765 )   (164,033 )   (1,098,774 )   (310,015 )   (46,238 )   (307,257 )
Add:                      
Income tax 3,194     476     3,405     3,335     497     1,528  
Finance costs 9,147     1,364     7,272     4,058     605     3,980  
Depreciation and amortization expenses 174,062     25,962     121,063     56,249     8,390     48,036  
EBITDA (913,362 )   (136,231 )   (967,034 )   (246,373 )   (36,746 )   (253,713 )

GIBRALTAR and FRANKFURT, Germany and NEW YORK and HONG KONG, Nov. 20, 2026 (GLOBE NEWSWIRE) — Bullish (NYSE:BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, today received System and Organization Controls (SOC) 1 Type 2 and SOC 2 Type 2 reports following the completion of examination engagements conducted by Deloitte1. The reports are for internal controls related to the digital assets exchange and associated custody services offered to customers onboarded with Bullish (GI) Ltd, Bullish Europe GmbH, Bullish US Operations LLC and Bullish HK Markets Limited for the year ending December 31, 2025. They are available to Bullish’s customers and their independent auditors subject to terms and conditions.

The SOC framework, developed by the American Institute of Certified Public Accountants (AICPA), is a suite of service offerings CPAs may provide in connection with system-level controls of a service organization or entity-level controls of other organizations.

“Independent assurance is central to how institutional clients evaluate a digital asset platform, and our teams across Gibraltar, Frankfurt, New York and Hong Kong have worked diligently to align Bullish with these global standards,” said Chris Tyrer, President of Bullish Exchange. “The progression from Type 1 to Type 2 gives institutional customers and their auditors added assurance to engage with the platform at scale.”

About Bullish:

Bullish (NYSE: BLSH) is an institutionally focused global digital asset platform that provides regulated market infrastructure and information services. This includes Bullish Exchange – an institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Europe is regulated under MiCAR as a crypto asset service provider offering spot trading and custody services for digital assets.

Bullish is the parent company of CoinDesk, a leading provider of digital asset media and information services. CoinDesk’s offerings include: CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries; CoinDesk Data – a broad suite of digital asset market data and analytics, providing real-time insights into prices, trends and market dynamics; and CoinDesk Insights – a digital asset media and events provider and operator of coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy and blockchain technology.

For more information, please visit bullish.com and follow LinkedIn and X.

Legal Disclaimer

Digital assets and related products may be high risk. Not investment advice. Consult your professional advisor and trade responsibly. Available in select locations to eligible customers. Visit bullish.com/legal for important information about licenses, risk warnings and other disclosures.

Use Of Websites to Distribute Material Company Information:

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements and include, without limitation, statements relating to future events or Bullish’s future financial or operating performance, business strategy, and potential market opportunity. Such forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Bullish, are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited, to our ability to grow our business and operations, including in new geographic locations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets and our industry. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and Bullish undertakes no duty to update these forward-looking statements.

Media contacts
media@bullish.com

1 Deloitte Touche Tohmatsu

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader: Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
Advanced Medical Solutions Group Plc
(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc
(d)        Date dealing undertaken: 19th November 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?
        If it is a cash offer or possible cash offer, state “N/A”
N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received
Ordinary shares Purchase 33,257 282.75 282.5

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
N/A N/A N/A N/A N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
N/A N/A N/A N/A N/A N/A N/A N/A

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
N/A N/A N/A N/A N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
N/A N/A N/A N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)        the voting rights of any relevant securities under any option; or
(ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

Date of disclosure: 20th November 2026
Contact name: Abhishek Gawde
Telephone number: +91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

Series  RIKB 29 0416 RIKS 29 0917
Settlement Date  11/25/2026 11/25/2026
Total Amount Allocated (MM)  3,160 5,440
All Bids Awarded At (Price / Yield)  100.783 / 7.350 98.985 / 3.884
Total Number of Bids Received  14 18
Total Amount of All Bids Received (MM)  4,360 8,411
Total Number of Successful Bids  10 10
Number of Bids Allocated in Full  10 10
Lowest Price / Highest Yield Allocated  100.783 / 7.350 98.985 / 3.884
Highest Price / Lowest Yield Allocated  100.890 / 7.300 99.048 / 3.860
Lowest Price / Highest Yield Allocated in Full  100.783 / 7.350 98.985 / 3.884
Weighted Average of Successful Bids (Price/Yield)  100.829 / 7.330 99.014 / 3.873
Best Bid (Price / Yield)  100.890 / 7.300 99.048 / 3.860
Worst Bid (Price / Yield)  100.675 / 7.400 98.830 / 3.944
Weighted Average of All Bids Received (Price / Yield)  100.801 / 7.340 98.984 / 3.885
Percentage Partial Allocation (Approximate)  100.00 % 100.00 %
Bid to Cover Ratio  1.38 1.55

Aspo Plc Stock exchange release 20 November 2026 at 13.30 EET

Aspo Plc’s financial reporting and Annual General Meeting in 2027

Aspo Plc (/Telko Group Plc) will publish the following financial reports in 2027:

  • Financial Statement release for 2026 on Thursday, February 18, 2027
  • Interim Report for January-March 2027 on Monday, April 26, 2027
  • Half-year Financial Report for January-June 2027 on Monday, July 19, 2027
  • Interim Report for January-September 2027 on Monday, October 25, 2027

The company’s Annual Review, including the Financial Statements and the Report of the Board of Directors for 2026, will be published during week 12/2027.

The company’s Annual General Meeting is planned to be held on Friday, April 23, 2027, in Helsinki, Finland. The Board of Directors will give a separate notice of the Annual General Meeting at a later date. Possible requests from shareholders to include matters on the agenda of the Annual General Meeting 2027 shall be sent to the company’s Board of Directors not later than March 3, 2027. The written request, together with an explanation or a draft resolution, shall be sent to Aspo Plc, Board of Directors, P.O. Box 70, FI-02151 Espoo, Finland.

In connection with the potential partial demerger of Aspo Plc, the company is intended to be renamed Telko Group Plc.

Aspo Plc

DISTRIBUTION:
Nasdaq Helsinki
Key media
www.aspo.com

Additional information:

More information about the partial demerger: aspo.com/demerger

Susanna Hietanen, Head of Communications and IR, Aspo Plc, tel. +358 50 3595 701, susanna.hietanen@aspo.com

Aspo creates value by owning and developing business operations sustainably and in the long term. Aspo’s businesses – ESL Shipping and Telko – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 650 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia.

Aspo is listed on Nasdaq Helsinki and is headquartered in Finland.

Aspo – Sustainable value creation

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.